Erschienen in:
17.11.2020 | Original Contributions
Bariatric Enhanced Recovery Protocol: a Community Quality Perspective
verfasst von:
Nicholas Gastaldo, Ryan Fitzgerald, Kelly Bahr, Joseph N. Gabra, Lance Talmage, Walter Chlysta, Christopher R. Daigle
Erschienen in:
Obesity Surgery
|
Ausgabe 3/2021
Einloggen, um Zugang zu erhalten
Abstract
Introduction
Bariatric enhanced recovery protocols can decrease length of stay (LOS) and hospital costs without compromising patient safety. Increased data is needed to compare patient outcomes before and after application of enhanced recovery pathways. We present a bariatric enhanced recovery protocol (BERP) at a community hospital. The objectives were to decrease hospital LOS and reduce schedule II substance use (medications with a high potential for abuse, potentially resulting in psychological or physical dependence), without compromising patient safety.
Methods
This was a combined retrospective and prospective analysis of all patients undergoing bariatric surgery by two surgeons from September 2016 to April 2018. Mann-Whitney U, Pearson chi-square, and Fisher’s exact tests were used to compare demographics, comorbidities, and outcomes.
Results
Two hundred patients were evaluated. Overall median (interquartile range) age was 43.0 (36.0–54.0) years and body mass index (BMI) was 45.0 (40.6–50.3) kg/m2. Pre-protocol mean hospital LOS was 2.3 days while enhanced recovery protocol patients mean LOS was 1.4 days (p < 0.001). Sixty-five percent of BERP patients were discharged on hospital day 1, while no patients prior to the protocol were discharged before hospital day 2. Only 9% of BERP patients were discharged with schedule II medications, compared to 100% of the pre-protocol patients (p < 0.001). Intraoperative, in-hospital, and 30-day complication rates were not statistically significant between the two groups.
Conclusion
Community hospitals can reduce length of stay and narcotic prescribing without compromising safety-related outcomes. Significant reductions in the amount of schedule II medications can be achieved when using multimodal enhanced recovery protocol approaches.